Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I vote 4, 7, 11 and 12
Not true for Medicare. You can’t use the coupon
Ralphey is not the problem. As a primary care doc I too find insurance blocking this due to cost. Medicare is impossible as coupons can’t be used.
Another study that has probably been posted and discussed
https://onlinelibrary.wiley.com/doi/full/10.1111/jcmm.15575
https://clinicaltrials.gov/ct2/show/NCT04460651
New study using high dose Vascepa for prevention of COVID 19
Physicians don’t usually choose what generic is dispensed. The pharmacy or drug benefit company controls this.
I am a family doc. I do not see a big uptake. I have 3 nurse practitioners that I have made aware of Vascepa. One is taking it.
Bfost, I agree with your numbers. I am getting emails frequently advertising Vascepa. I do not see drug reps. I believe primary care docs are hearing from AMRN. My company does not allow drug reps in the office.
New presentation at ACC re EPA/ AA levels. This could be significant.
#ACC20 Late-Breaking Clinical Trials
— BIOTECH (@_B_I_O_T_E_C_H_) February 3, 2020
411-14 - Eicosapentaenoic Acid Levels in REDUCE-IT and Cardiovascular Outcomes $AMRN pic.twitter.com/4sYp5u8xq5
The date was 9/17/19 so not very old. I apologize it this was already discussed.
Citi added AMRN to their top 5 small biotechs
https://www.barrons.com/articles/sarepta-amarin-stocks-citi-top-5-list-biotech-51568729374
https://www.medscape.org/sites/townhall/public/omega-3?src=soc_tw_190807_mscpedu_liveev_card_cvd&faf=1
Dr Bhatt is presenting in France Sept 2
Dr Byatt on Twitter suggests sending the NEJM article and a copy of ADA guidelines to the insurance company if the refuse to pay for Vascepa
Another inside seller reported reported
I see where David Stack a director sold over 100 k shares
https://www.businesswire.com/news/home/20190513005207/en/Sesen-Bio-Reports-Quarter-2019-Financial-Results
Sesen to meet with the FDA soon
Thanks
I got the same email tonight
No, standard practice would be to do this in the next visit. I do no have patients on generic Lovaza. People take otc fish oil. It will take education to change this.
I generally see a patient who stable every six months. Prescriptions are either for 30 d with 5 refills or 90 d with 1 refill. This is often determined by the insurance
I agree too many primary care docs are not aware of the Reducit study. Also our organization does not allow drug reps in our offices. This will slow uptake and it may be why TV ads are happening. Insurance needs to get on board to decrease co pays even with the discount card.
Family doctors have 3 years training post med school. I am one and I understand Vascepa and prescribe it
Sesen Bio Announces Vicinium Granted Fast Track Designation by FDA for Treatment of Non-Muscle Invasive Bladder Cancerhttps://finance.yahoo.com/news/sesen-bio-announces-vicinium-granted-103000195.html
New CEO appointed
Thomas Cannelloni DMV was involved with getting Contrave approved
Actually Sesen is a ancient symbol it the lotus flower according to the press release. It represents life.
Presentation today
The company is presenting today in Boston at the DNA damage response summit. I do not see any web link.
The recommendation from the CDC is that everyone over 6 months of age should get the flu shot unless there is a history of severe allergic reactions.
TapImmune to Present at the 2017 BioFlorida Conference
https://finance.yahoo.com/news/tapimmune-present-2017-bioflorida-conference-103000391.html
Auris Medical Announces Share Purchase Agreements with Lincoln Park Capital Fund, LLC
https://finance.yahoo.com/news/auris-medical-announces-share-purchase-104701671.html
Bad science
The statin article was published in The Annals of Internal Medicine. This is a reputable journal. I do not see where this is supported by pharma. I believe in Vascepa however statins do save lives.
I am sure the combined Vascepa-statin therapy will be even more of a life saver.
I presently prescribe statins daily.
New study concerning statins
http://www.reuters.com/article/us-health-heart-idUSKBN1A92LP
Stopping statins may no be a good idea.
The insurance companies control what can be written. Formularies and copay are road blocks to prescribing. This is based on my experience as a primary care provider
PCSK9's may have outcome data this summer?
Sheff just got back in
Just met with the Kowa drug rep. He left me the Anchor study but he reported he is not allowed to discuss Jelsis yet.
There is a cost problem. I wrote for a patient this week who has a part D Medicare plan. It was tier 4 and he could not use the coupon. He has Iiver issues so fibrates are not an option. Lovaza is also tier 4. The pharmacist recommended colystyramine. Needless to say he did not fill the prescription.
According to fiercebiotech.com Merck's Improve-it study may be positive for Zetia and Vytorin.
Adam also bashed AMRN prior to their failed Adcom. It was if he knew what was going to happen.